J. Josan

发表

Heterobivalent ligands target cell-surface receptor combinations in vivo

Liping Xu, Robert J Gillies, Josef Vagner, 2012, Proceedings of the National Academy of Sciences.

Designer antiandrogens join the race against drug resistance

J. Katzenellenbogen, J. Josan, 2013, eLife.

a cancer drug and its receptor, it may be possible to strategically redesign existing drugs and win the race against mutations that lead to drug resistance in prostate cancer.

J. Katzenellenbogen, J. Josan, 2013 .

Tumor Targeting, Pharmacokinetics and Biodistribution of a Near Infrared Fluorescent-labeled δ -Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5

D. Morse, J. Vagner, V. Estrella, 2016 .

Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

R. Gillies, V. Hruby, Kevin N Sill, 2011, Journal of medicinal chemistry.

Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R).

R. Gillies, V. Hruby, J. Vagner, 2007, Bioconjugate chemistry.

Solid-Phase Synthesis of Heterobivalent Ligands Targeted to Melanocortin and Cholecystokinin Receptors

R. Gillies, V. Hruby, J. Vagner, 2008, International Journal of Peptide Research and Therapeutics.

Enhanced targeting with heterobivalent ligands

R. Gillies, V. Hruby, R. Lynch, 2009, Molecular Cancer Therapeutics.

Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging.

R. Gillies, V. Hruby, D. Morse, 2009, Organic letters.

CMR 2007: 4.02: A novel targeting approach to molecular imaging based on heteromultivalency

Robert J. Gillies, Jatinder S. Josan, Josef Vagner, 2007 .

Separation of stereoisomers of 7-oxa-bicyclo[2.2.1]heptene sulfonate (OBHS), a Selective Estrogen Receptor Modulator (SERM), via chiral stationary phases using SFC/UV and SFC/MS.

M. Ashraf-khorassani, J. Josan, P. Balasubramanyam, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Solid-Phase Synthetic Strategy & Bioevaluation of a Labeled δ Opioid Receptor Ligand Dmt-Tic-Lys for In Vivo Imaging

R. Gillies, V. Hruby, D. Morse, 2009 .

Fluorescent and lanthanide labeling for ligand screens, assays, and imaging.

V. Hruby, R. Lynch, M. Pagel, 2011, Methods in molecular biology.

Synthesis, receptor binding, and activation studies of N(1)-alkyl-L-histidine containing thyrotropin-releasing hormone (TRH) analogues.

N. Kaur, M. Gershengorn, Vikramdeep Monga, 2006, Bioorganic & medicinal chemistry.

Cell-specific targeting by heterobivalent ligands.

R. Gillies, V. Hruby, R. Lynch, 2011, Bioconjugate chemistry.

Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.

V. Hruby, Jongphil Kim, D. Morse, 2016, Molecular pharmaceutics.

Predictive features of ligand‐specific signaling through the estrogen receptor

O. Elemento, J. Nwachukwu, S. Srinivasan, 2016, Molecular systems biology.

Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and delta-opioid receptors.

R. Gillies, V. Hruby, D. Morse, 2008, Angewandte Chemie.

Synthesis of bivalent MSH ligands and evaluation of their binding to hMC4R using MSH lanthaligand.

R. Gillies, V. Hruby, J. Vagner, 2009, Advances in experimental medicine and biology.

Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

R. Gillies, V. Hruby, D. Morse, 2011, Journal of medicinal chemistry.

Fluorescent and lanthanide labeling for ligand screens, assays, and imaging.

V. Hruby, R. Lynch, M. Pagel, 2011, Methods in molecular biology.

MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression

B. Katzenellenbogen, Julie A. Pollock, J. Katzenellenbogen, 2017, Hormones and Cancer.